Zentek

Zentek has announced a strategic partnership with Al-Ramez International Group, facilitated through Saudi Excellence Holding Company. The partnership aims to foster innovation and commercialization of advanced technologies in the Kingdom of Saudi Arabia (KSA) and the Middle East and North Africa (MENA) region.

Under the Memorandum of Understanding (MOU), Zentek will contribute its intellectual property, product licensing, and research and development expertise. In turn, Al-Ramez International Group will provide marketing support, investor relations, financing, and market access within KSA and MENA. The collaboration seeks to achieve several objectives, including the development of a graphene production facility in KSA, a commercialization hub for Zentek's graphene technologies, and the expansion of biotechnology research. The agreement also aims to secure strategic investment in resources to support the North American supply chain for advanced materials and establish a research and development center for aptamer technology in conjunction with a Saudi university.

Zentek has announced that its wholly-owned subsidiary Triera Biosciences has received a CAD$1.1 million (around USD$791,000) Government of Canada contract to test its multivalent aptamer technology for the rapid drug discovery of therapeutics or prophylactics of highly pathogenic avian influenza (“HPAI”) A(H5N1).

Triera was awarded a these funds through Innovation, Science and Economic Development Canada's (“ISED”) Innovative Solutions Canada (“ISC”) program: Health Advanced And Emerging Medical Technologies. Triera’s multivalent aptamer technology was selected for its potential to be used as a rapid drug development platform.

Zentek has provided an update on recent commercialization activities for its ZenGUARD™ Antimicrobial Surgical Masks.

As previously announced in July 2024, the Company embarked on a Canada-wide sampling program for dental professionals facilitated by Henry Schein Inc. that saw ZenGUARD™ Antimicrobial Surgical Masks included in product shipments to Henry Schein customers across Canada. As a result of this program, the Company is now reportedly seeing increased demand from Henry Schein, the world’s largest provider of health care solutions to office-based dental and medical practitioners with a presence in 33 countries.

Zentek has announced that it has closed its non-brokered private placement for gross proceeds of CAD$3,069,950 (around USD$2,254,000). Net proceeds of the Offering will be used for working capital and general corporate purposes.

Zentek's CEO, Greg Fenton, commented: "We would like to thank all those who participated in the Offering. This funding will allow us to immediately allocate resources to our international market expansion strategy, where ZenGUARD-coated HVAC filters can play a meaningful role in an entity's sustainability objectives."

Zentek has reported its earnings for the first quarter ended June 30, 2024. For the first quarter, the Company reported sales was CAD 0.005489 million (USD$0.004). Net loss was CAD 2.55 million (around USD$1,857,000) compared to CAD 3.16 million (around USD$2,300,000) a year ago.

Basic loss per share from continuing operations was CAD 0.03 compared to CAD 0.03 a year ago. Diluted loss per share from continuing operations was CAD 0.03 compared to CAD 0.03 a year ago.

Zentek has announced that it will embark on a Canada-wide sampling program for dental professionals facilitated by Henry Schein that will see ZenGUARD™ Antimicrobial Surgical Masks included in product shipments to Henry Schein customers.

In addition to offering dental practitioners and their patients a surgical mask with improved protection against infectious agents, ZenGUARD™ Antimicrobial Surgical Masks are also said to be proven to eliminate 99.9% of bacteria, which can collect on the skin when wearing a surgical mask for extended periods and cause acne. The Company believes this program will introduce ZenGUARD™ Antimicrobial Surgical Masks and this unique value proposition to nearly all Henry Schein customers across Canada.

Zentek has announced its intention to complete a non-brokered private placement of up to CAD$3 million (around USD$2,180,000). Gross proceeds of the offering will be used for working capital and general corporate purposes.

In May 2024, Zentek received a patent by the Canadian Intellectual Property Office, titled: Graphene Oxide-Cationic Silver (GO-Ag+) Nanocomposites and Their Use as a Broad-Spectrum Antimicrobial Agent. In December 2023, Zentek announced the launch of Triera Biosciences as its wholly owned subsidiary for its aptamer platform technology. Then, in May 2024, Zentek and Triera Biosciences announced achieving positive results against Avian Influenza (H5N1) using their Multivalent Aptamer Technology. 

Canada-based Zentek has announced the launch of Triera Biosciences as its wholly owned subsidiary for its aptamer platform technology. This subsidiary now owns the exclusive, global licensing rights for all aptamer-based technology from the collaboration with McMaster University.

The Company is repotedly taking this action following the strong, consistent pre-clinical results of its universal aptamer as a treatment against the SARS-CoV-2 virus including the latest Omicron XBB 1.5 variant and will continue to build upon its previous work on a rapid detection platform within the new subsidiary. Triera will offer a pure play in the biotech space when operated as an independent business and be more accessible to potential pharmaceutical partners, funders, and other interested parties.

Zentek recently announced a new research and development contract through Innovative Solutions Canada to test ZenARMOR™ nano-pigment in military grade, chromate-free, corrosion protection aerospace paint systems.

The testing will be conducted under the supervision of Dr. Qi Yang, and Dr. Naiheng Song, Research Officers at the National Research Council of Canada (NRC) Aerospace Research Centre’s Aerospace Manufacturing Technologies Centre (AMTC).

Zentek has announced a collaboration with Pattern Energy Group to optimize, test and validate Zentek’s icephobic coating for the wind turbine industry. The partnership is being supported financially by both the Natural Sciences and Engineering Research Council of Canada (“NSERC”) and PRIMA Quebec - Advanced Materials Moving Forward.

Pattern Energy develops, constructs, owns, and operates wind turbines and understands the lost efficiency and potential damage to the wind turbine itself and its surroundings that comes from ice accretion on these structures.